Salvia BioElectronics: A New Dawn for Migraine Sufferers
May 29, 2025, 12:48 am
Location: Netherlands, North Holland, Amsterdam
Employees: 11-50
Founded date: 2017
In the world of chronic pain, migraines reign supreme. They are not just headaches; they are life-altering storms that can sweep away productivity, joy, and social connections. For millions, the search for relief is a relentless journey. Enter Salvia BioElectronics, a Dutch startup poised to change the landscape of migraine treatment with its innovative MySalvia Therapy. Recently, the company secured €53 million in funding, a financial lifeline that could help many reclaim their lives.
Founded in 2017 in Eindhoven, Salvia BioElectronics is on a mission. Its flagship product, MySalvia Therapy, is a neuromodulation solution designed to tackle chronic migraines head-on. The company’s approach is simple yet revolutionary. It employs two ultra-thin implants, strategically placed beneath the skin of the forehead and the back of the head. These implants work in tandem with an external wearable device, allowing patients to activate targeted stimulation whenever they feel a migraine coming on. It’s like having a personal shield against the onslaught of pain.
The recent funding round was led by Innovation Industries, a European DeepTech venture capital firm, with participation from several notable investors. This strong backing signals confidence in Salvia’s vision. The funds will not only support the completion of the pivotal RECLAIM clinical study but also pave the way for regulatory approvals in the U.S., Europe, and Australia. This is crucial, as the company aims to bring its life-changing therapy to market.
Chronic migraines are a significant burden, costing the economy an estimated €96.6 billion annually in lost productivity and healthcare expenses in the EU and U.S. alone. Current treatments often fall short, leaving many patients feeling hopeless. The reality is stark: most chronic migraine sufferers discontinue their medication within the first year due to ineffectiveness. Salvia aims to fill this gap with a patient-centered approach that prioritizes meaningful relief.
The MySalvia Therapy is not just another treatment; it represents a paradigm shift. Traditional migraine therapies often involve a cocktail of medications, each with its own side effects and limitations. In contrast, Salvia’s solution is minimally invasive and designed for patient control. Imagine being able to take charge of your pain management with the press of a button. This empowerment could be a game-changer for those who feel trapped by their condition.
The technology behind MySalvia Therapy is rooted in neuromodulation, a field that has gained traction in recent years. Neuromodulation involves altering nerve activity through targeted stimulation, offering a new avenue for pain management. Salvia’s approach is particularly appealing because it holds the promise of reducing both the frequency and intensity of migraine attacks. Early clinical data suggests that patients may experience significant improvements, which is a beacon of hope for many.
Salvia’s implants are designed to be discreet and less invasive than conventional options. This means shorter recovery times and a lower risk of complications. For patients, this translates to a more comfortable experience and a quicker return to their daily lives. The elegance of the design is matched only by its functionality, making it a compelling option for those who have struggled with traditional treatments.
The FDA has recognized the potential of MySalvia Therapy by granting it Breakthrough Device Designation. This designation accelerates the path to market, allowing Salvia to expedite its regulatory processes. The company is currently conducting the RECLAIM study, a multi-center, double-blind, sham-controlled trial that aims to validate the efficacy of its therapy. With U.S. trials on the horizon, the anticipation is palpable.
Salvia BioElectronics is not alone in its quest. The medtech landscape is buzzing with innovators exploring alternatives to pharmacological treatments. Neuromodulation is becoming a hotbed of activity, with several companies vying to redefine how we approach chronic pain and neurological disorders. Salvia stands out with its focus on migraines, a condition that has long been underserved.
The journey ahead is filled with challenges, but the potential rewards are immense. If successful, Salvia could provide a lifeline to millions of chronic migraine sufferers. The vision is clear: to restore freedom and quality of life to those held captive by their pain. The stakes are high, but so are the hopes of countless individuals who dream of a future free from the shackles of migraines.
In conclusion, Salvia BioElectronics is not just another startup; it is a beacon of hope in the murky waters of chronic pain management. With its innovative MySalvia Therapy, the company is poised to make waves in the migraine treatment landscape. The recent funding is a testament to the belief in its mission. As clinical trials progress and regulatory approvals loom, the world watches closely. For those living with chronic migraines, this could be the dawn of a new era—one where pain no longer dictates the terms of life.
Founded in 2017 in Eindhoven, Salvia BioElectronics is on a mission. Its flagship product, MySalvia Therapy, is a neuromodulation solution designed to tackle chronic migraines head-on. The company’s approach is simple yet revolutionary. It employs two ultra-thin implants, strategically placed beneath the skin of the forehead and the back of the head. These implants work in tandem with an external wearable device, allowing patients to activate targeted stimulation whenever they feel a migraine coming on. It’s like having a personal shield against the onslaught of pain.
The recent funding round was led by Innovation Industries, a European DeepTech venture capital firm, with participation from several notable investors. This strong backing signals confidence in Salvia’s vision. The funds will not only support the completion of the pivotal RECLAIM clinical study but also pave the way for regulatory approvals in the U.S., Europe, and Australia. This is crucial, as the company aims to bring its life-changing therapy to market.
Chronic migraines are a significant burden, costing the economy an estimated €96.6 billion annually in lost productivity and healthcare expenses in the EU and U.S. alone. Current treatments often fall short, leaving many patients feeling hopeless. The reality is stark: most chronic migraine sufferers discontinue their medication within the first year due to ineffectiveness. Salvia aims to fill this gap with a patient-centered approach that prioritizes meaningful relief.
The MySalvia Therapy is not just another treatment; it represents a paradigm shift. Traditional migraine therapies often involve a cocktail of medications, each with its own side effects and limitations. In contrast, Salvia’s solution is minimally invasive and designed for patient control. Imagine being able to take charge of your pain management with the press of a button. This empowerment could be a game-changer for those who feel trapped by their condition.
The technology behind MySalvia Therapy is rooted in neuromodulation, a field that has gained traction in recent years. Neuromodulation involves altering nerve activity through targeted stimulation, offering a new avenue for pain management. Salvia’s approach is particularly appealing because it holds the promise of reducing both the frequency and intensity of migraine attacks. Early clinical data suggests that patients may experience significant improvements, which is a beacon of hope for many.
Salvia’s implants are designed to be discreet and less invasive than conventional options. This means shorter recovery times and a lower risk of complications. For patients, this translates to a more comfortable experience and a quicker return to their daily lives. The elegance of the design is matched only by its functionality, making it a compelling option for those who have struggled with traditional treatments.
The FDA has recognized the potential of MySalvia Therapy by granting it Breakthrough Device Designation. This designation accelerates the path to market, allowing Salvia to expedite its regulatory processes. The company is currently conducting the RECLAIM study, a multi-center, double-blind, sham-controlled trial that aims to validate the efficacy of its therapy. With U.S. trials on the horizon, the anticipation is palpable.
Salvia BioElectronics is not alone in its quest. The medtech landscape is buzzing with innovators exploring alternatives to pharmacological treatments. Neuromodulation is becoming a hotbed of activity, with several companies vying to redefine how we approach chronic pain and neurological disorders. Salvia stands out with its focus on migraines, a condition that has long been underserved.
The journey ahead is filled with challenges, but the potential rewards are immense. If successful, Salvia could provide a lifeline to millions of chronic migraine sufferers. The vision is clear: to restore freedom and quality of life to those held captive by their pain. The stakes are high, but so are the hopes of countless individuals who dream of a future free from the shackles of migraines.
In conclusion, Salvia BioElectronics is not just another startup; it is a beacon of hope in the murky waters of chronic pain management. With its innovative MySalvia Therapy, the company is poised to make waves in the migraine treatment landscape. The recent funding is a testament to the belief in its mission. As clinical trials progress and regulatory approvals loom, the world watches closely. For those living with chronic migraines, this could be the dawn of a new era—one where pain no longer dictates the terms of life.